Details for Patent: 12,049,628
✉ Email this page to a colleague
Which drugs does patent 12,049,628 protect, and when does it expire?
Patent 12,049,628 protects AMVUTTRA and is included in one NDA.
This patent has fifty-one patent family members in thirty-three countries.
Drugs Protected by US Patent 12,049,628
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | AMVUTTRA | vutrisiran sodium | SOLUTION;SUBCUTANEOUS | 215515-001 | Jun 13, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,049,628
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3329002 | ⤷ Subscribe | 301216 | Netherlands | ⤷ Subscribe |
| European Patent Office | 3329002 | ⤷ Subscribe | PA2023505 | Lithuania | ⤷ Subscribe |
| European Patent Office | 3329002 | ⤷ Subscribe | 7/2023 | Austria | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
